StreetInsider.com News Articles

Form 8-K Microbot Medical Inc. For: Mar 10

Tue, 10 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260310/26136046.html

Form 8-K Microbot Medical Inc. For: Mar 10

Tue, 10 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260310/26136046.html

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first time the Company has been invited to participate in this conference, reflecting growing market interest in the Company. Harel Gadot, CEO, President & Chairman will present live at 8:40 am ET on Thursday, March 19th. Mr. Gadot will highlight recent achievements from LIBERTY’s limited market release and review key

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release

HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first time the Company has been invited to participate in this conference, reflecting growing market interest in the Company. Harel Gadot, CEO, President &

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release

Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

Tue, 10 Mar 2026 08:30:00 -0400

Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release

Microbot Medical cites radiation protection policy for robotic system

Wed, 04 Mar 2026 08:32:08 -0400

Microbot Medical Inc. (NASDAQ: MBOT) said its LIBERTY Endovascular Robotic System addresses radiation exposure concerns following the American Medical Association's adoption of a policy to strengthen protections for healthcare professionals from ionizing radiation in late 2025.

The AMA policy emphasizes research into health effects of cumulative radiation exposure, effectiveness of personal protection equipment, and education to minimize occupational risk for physicians and patients. The medical association's guidance comes as prolonged radiation exposure can lead to cancer, cardiovascular disease, reproductive health effects, and cataracts.

Microbot's LIBERTY system allows physicians to perform procedures remotely from the radiation source. The company reported a 92% relative

Form 8-K Microbot Medical Inc. For: Mar 04

Wed, 04 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26107741.html

Form 8-K Microbot Medical Inc. For: Mar 04

Wed, 04 Mar 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260304/26107741.html

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

Wed, 04 Mar 2026 08:30:00 -0400

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers

HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for health care professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

Wed, 04 Mar 2026 08:30:00 -0400

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

Wed, 04 Mar 2026 08:30:00 -0400

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

Wed, 04 Mar 2026 08:30:00 -0400

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers

Microbot Medical maintains operations amid geopolitical tensions

Tue, 03 Mar 2026 09:00:57 -0400

Microbot Medical Inc. (NASDAQ: MBOT) stated that its operations in the United States and Israel remain unaffected by current geopolitical events in the Middle East. The medical device company reported that all personnel continue normal operations and its manufacturing partner remains fully functional.

The company's commercial focus centers on the U.S. market following recent FDA clearance of its LIBERTY Endovascular Robotic System. Operations are managed by a U.S.-based commercial team headquartered in Hingham, Massachusetts. Microbot Medical maintains sufficient inventory in the United States to support existing customers and is building additional stock through a U.S.-based third-party logistics partner.

The company plans a

Form 8-K Microbot Medical Inc. For: Mar 03

Tue, 03 Mar 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260303/26097664.html

Form 8-K Microbot Medical Inc. For: Mar 03

Tue, 03 Mar 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260303/26097664.html

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

Tue, 03 Mar 2026 09:00:00 -0400

HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional.

Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the